| 刊名 | Medicinal Plant |
| 作者 | Zhenxing CAI, Guanghui CHEN, Zhengteng YANG, Jiabao MA, Jinhua LIU, Xiaoxia LI, Jing FU, Xiaodong HUANG |
| 作者单位 | 1.The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China; 2.Guangxi University of Chinese Medicine, Nanning 530200, China |
| DOI | DOI:10.19600/j.cnki.issn2152-3924.2026.02.004 |
| 年份 | 2026 |
| 刊期 | 2 |
| 页码 | 16-19，24 |
| 关键词 | Dujieqing Pills, Acute toxicity, Chronic toxicity, Preclinical safety evaluation |
| 摘要 | [Objectives] To investigate the acute and chronic toxic reactions of Dujieqing Pills and provide a basis for its safe clinical use. [Methods] The acute toxicity test employed the maximum dose tolerance test. The chronic toxicity experiment divided rats into low, medium, and high dose groups, receiving 10, 20, and 40 times the proposed clinical dose, respectively. Administration continued for 13 weeks, during which organ coefficients, histopathological changes, and toxicity reversibility were observed. [Results] In the acute toxicity experiment, the maximum tolerated gavage dose of Dujieqing Pills for KM mice was 84 g/(kg·d), with no significant toxic reactions observed at this dose. In the chronic toxicity experiment, SD rats administered the pills continuously for 13 weeks showed no significant abnormalities in appearance, behavioral activities, body weight, organ coefficients, or histopathological examinations. [Conclusions] No significant toxic reactions were observed in either the acute or chronic toxicity tests, suggesting that Dujieqing Pills exhibit good safety for single or long-term use at the proposed clinical dose. |
